CD8A and neoplasm: PX-478, combined with anti-PD-L1 antibody, decreases tumor growth, and increases survival by activating dendritic and CD8 T cells. PX-478 marked antitumor activity in large tumor xenografts, accompanied by massive apoptosis. (NCT00522652)